Vinícius Leal Pitcella
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Vinícius Leal Pitcella has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Carolina Paula de Souza Moreira
Research Department, Pharmaceutical Technology Development Service, Ezequiel Dias Foundation (FUNED), Brazil
2 shared publications - Gustavo Henrique Oliveira Costa
Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Avenida Presidente Antônio Carlos 6627, Belo Horizonte, MG 31270-901, Brazil
2 shared publications - José Eduardo Gonçalves
Laboratório de Controle de Qualidade, Departamento de Produtos Farmacêuticos, Faculdade de Farmácia UFMG Belo Horizonte Brazil
2 shared publications - João Victor Vanolli Protti
Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil
2 shared publications - Renata Barbosa de Oliveira
Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil
2 shared publications - Susana Johann
Universidade Federal de Minas Gerais, Brazil
2 shared publications
Latest Publications
- Open Access
- 16 January 2025
- Published by MDPI AG in Journal of Fungi
- Vol. 11 (1) , 69
Novel 2-Thiazolylhydrazone with Druggable Properties for Antifungal Application
Fungal infections have become a growing concern in healthcare, particularly in immunocompromised individuals, with species like Candida, Cryptococcus, and Sporothrix posing significant challenges due to rising resistance and limited treatment options. In response, novel antifungal agents are being explored, including thiazolyl hydrazones. This study focuses on the development of a novel thiazolylhydrazone derivative, RW3. RW3 was synthesized to improve its water solubility and pharmacokinetic properties. The compound demonstrated a broad antifungal spectrum, particularly effective against Cryptococcus neoformans and Candida auris, with minimal irritant potential and low cytotoxicity. RW3 showed favorable solubility and high intestinal permeability, indicating potential for oral administration. The results suggest RW3 as a promising lead for further development as a therapeutic agent for systemic fungal infections. These findings underscore the importance of optimizing drug properties to enhance efficacy and safety profiles, opening the path for the development of innovative antifungal treatments.
- 16 January 2025
- Published by MDPI AG in Journal of Fungi
- Vol. 11 (1) , 69
Open AccessNovel 2-Thiazolylhydrazone with Druggable Properties for Antifungal Application
Fungal infections have become a growing concern in healthcare, particularly in immunocompromised individuals, with species like Candida, Cryptococcus, and Sporothrix posing significant challenges due to rising resistance and limited treatment options. In response, novel antifungal agents are being explored, including thiazolyl hydrazones. This study focuses on the development of a novel thiazolylhydrazone derivative, RW3. RW3 was synthesized to improve its water solubility and pharmacokinetic properties. The compound demonstrated a broad antifungal spectrum, particularly effective against Cryptococcus neoformans and Candida auris, with minimal irritant potential and low cytotoxicity. RW3 showed favorable solubility and high intestinal permeability, indicating potential for oral administration. The results suggest RW3 as a promising lead for further development as a therapeutic agent for systemic fungal infections. These findings underscore the importance of optimizing drug properties to enhance efficacy and safety profiles, opening the path for the development of innovative antifungal treatments.
- Open Access
- 7 January 2025
- Published by MDPI AG in Preprints.org
Novel 2-Thiazolylhydrazone with Druggable Properties for Antifungal Application
Fungal infections have become a growing concern in healthcare, particularly in immuno-compromised individuals, with species like Candida, Cryptococcus, and Sporothrix pos-ing significant challenges due to rising resistance and limited treatment options. In re-sponse, novel antifungal agents are being explored, including thiazolyl hydrazones. This study focuses on the development of a novel thiazolylhydrazone derivative, RW3. RW3 was synthesized to improve water solubility and pharmacokinetic properties. The com-pound demonstrated a broad antifungal spectrum, particularly effective against Crypto-coccus neoformans and Candida auris, with minimal irritant potential and low cytotoxi-city. RW3 showed favorable solubility and high intestinal permeability, indicating poten-tial for oral administration. The results suggest RW3 as a promising lead for further de-velopment as a therapeutic agent for systemic fungal infections. These findings under-score the importance of optimizing drug properties to enhance efficacy and safety profiles, opening the path for the development of innovative antifungal treatments.
- 7 January 2025
- Published by MDPI AG in Preprints.org
Open AccessNovel 2-Thiazolylhydrazone with Druggable Properties for Antifungal Application
Fungal infections have become a growing concern in healthcare, particularly in immuno-compromised individuals, with species like Candida, Cryptococcus, and Sporothrix pos-ing significant challenges due to rising resistance and limited treatment options. In re-sponse, novel antifungal agents are being explored, including thiazolyl hydrazones. This study focuses on the development of a novel thiazolylhydrazone derivative, RW3. RW3 was synthesized to improve water solubility and pharmacokinetic properties. The com-pound demonstrated a broad antifungal spectrum, particularly effective against Crypto-coccus neoformans and Candida auris, with minimal irritant potential and low cytotoxi-city. RW3 showed favorable solubility and high intestinal permeability, indicating poten-tial for oral administration. The results suggest RW3 as a promising lead for further de-velopment as a therapeutic agent for systemic fungal infections. These findings under-score the importance of optimizing drug properties to enhance efficacy and safety profiles, opening the path for the development of innovative antifungal treatments.